A 24-week, Multinational, Multicentre, Randomised, Open Label, Parallel-group Treat-to-target Trial to Compare Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
Phase of Trial: Phase IV
Latest Information Update: 31 May 2018
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 26 Apr 2017 Status changed from active, no longer recruiting to completed.
- 03 Oct 2016 Status changed from recruiting to active, no longer recruiting.